Volume 10 Number 2 2026
Cellular Reprogramming Strategies for Age-Related Macular Degeneration From iPSCs to In Vivo Therapy
Andrew Johan 1*, Irene Uli 2, Yosefani Fortunella Yasmine 2
Integrative Biomedical Research 10 (2) 1-8 https://doi.org/10.25163/biomedical.10210927
Submitted: 20 August 2026 Revised: 12 October 2026 Accepted: 21 October 2026 Published: 23 October 2026
Age-related macular degeneration (AMD) remains one of the leading, and most stubborn, causes of irreversible central vision loss in older adults, and for a long time clinicians could do little more than slow its march. That picture has begun to change. This review traces how cellular reprogramming technologies — from induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) transplantation to direct lineage transdifferentiation and, more recently, in vivo partial epigenetic reprogramming — are reshaping what regenerative ophthalmology can offer. Background: since Takahashi and Yamanaka's original demonstration that four transcription factors can reset adult somatic cells to pluripotency, the field has moved from single-patient autologous grafts toward banked, HLA-matched allogeneic lines and, in parallel, toward strategies that bypass pluripotency altogether. Methods: we conducted a structured, PubMed-oriented narrative synthesis of peer-reviewed literature, clinical trial registries, and preprint sources addressing stem cell platforms, reprogramming delivery systems, direct transdifferentiation, and partial in vivo rejuvenation relevant to retinal degeneration, screened for relevance and synthesized thematically rather than through formal meta-analysis. Results: autologous iPSC-RPE sheets demonstrated long-term graft survival without systemic immunosuppression, while allogeneic HLA-banked lines improved scalability at some immunological cost; non-integrating delivery platforms (Sendai virus, AAV, modified mRNA) meaningfully reduced insertional mutagenesis risk relative to integrating vectors; and OSK-based partial reprogramming reversed markers of retinal ganglion cell aging in preclinical models, now advancing to early-phase human trials. Conclusion: cellular reprogramming has moved from proof-of-concept to an increasingly diversified therapeutic toolkit for AMD, though genomic stability, manufacturing cost, and regulatory clarity remain unresolved before these approaches can be considered routine care.
Keywords: age-related macular degeneration; induced pluripotent stem cells; retinal pigment epithelium; cellular reprogramming; transdifferentiation; partial epigenetic reprogramming; regenerative ophthalmology
Abdelnaby, M., Galiakberova, A., & Dashinimaev, E. (2026). AAV vectors in regenerative medicine and cellular reprogramming: Potential, pitfalls, and specificity constraints. International Journal of Molecular Sciences, 27(06846). https://doi.org/10.3390/ijms2706846
Agarwal, S., Church, G. M., Collins, J. J., Irion, S., Loh, Y. H., & Daley, G. Q. (2010). Telomere maintenance and reprogramming kinetics in human T-cell-derived induced pluripotent stem cells. Cell Stem Cell, 7(4), 411--419. https://doi.org/10.1016/j.stem.2010.08.006
Ahmad, U., Kumar, D., & Faiyazuddin, M. (2025). Can iPSCs turn back time? Prospects and pitfalls in age reversal. Current Stem Cell Research & Therapy, 20(4). https://doi.org/10.2174/1574888x400606250721112037
Armstrong, L., Lako, M., Dean, W., & Stojkovic, M. (2005). Telomere maintenance and telomerase activity in human embryonic stem cells and induced pluripotent stem cells. Stem Cells, 23(8), 1056--1066. https://doi.org/10.1634/stemcells.2005-0210
Assis, R. I. F., Wiench, M., Silvério, K. G., da Silva, R. A., Feltran, G. S., Sallum, E. A., Casati, M. Z., Nociti, F. H., & Andia, D. C. (2018). RG108 increases NANOG and OCT4 in bone marrow-derived mesenchymal cells through global changes in DNA modifications and epigenetic activation. PLoS One, 13(11), e0207873. https://doi.org/10.1371/journal.pone.0207873
Banito, A., Rashid, S. T., Acosta, J. C., Li, S., Pereira, C. F., Geti, I., Cobb, A. M., Amaral, F. M., Griffiths, J. R., Bellamy, M., & Alderton, W. (2009). Senescence impairs successful reprogramming to pluripotent stem cells. Genes & Development, 23(18), 2134--2139. https://doi.org/10.1101/gad.173922.111
Batista, L. F. Z., Pech, M. F., Zhong, F. L., Nguyen, H. N., Xie, K. T., Zaug, A. J., Crary, S. M., Choi, J., Sebastiano, V., Cherry, A., Giri, N., Wernig, M., Alter, B. P., Cech, T. R., Savage, S. A., Reijo Pera, R. A., & Artandi, S. E. (2011). Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature, 474(7351), 399--404. https://doi.org/10.1038/nature10084
Bloor, A. J. C., Patel, A., Griffin, J. E., Gilleece, M. H., Radia, R., Yeung, D. T., Drier, D., Larson, L. S., Uenishi, G. I., Hei, D., Kelly, K., Slukvin, I., & Rasko, J. E. J. (2020). Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nature Medicine, 26(11), 1720--1725. https://doi.org/10.1038/s41591-020-1120-x
Chen, T., Chen, Z., Du, J., Zhang, M., Chen, Z., Gao, Q., Chen, A., Meng, Q., Sun, Y., Liu, Y., Song, L., Wang, X., Edavi, P. P., Xu, C., Zhang, H., Huang, J., & Jiang, Y. (2025). Reprogramming of iPSCs to NPCEC-like cells by biomimetic scaffolds for zonular fiber reconstruction. Bioactive Materials, 45, 446--458. https://doi.org/10.1016/j.bioactmat.2024.11.031
Chou, B. K., Mali, P., Huang, X., Ye, Z., Dowey, S. N., Resar, L. M., & Cheng, L. (2011). Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Research, 21(3), 518--529. https://doi.org/10.1038/cr.2011.23
Cichocki, F., Bjordahl, R., Goodridge, J. P., Mahmood, S., Gaidarova, S., Abujarour, R., Davis, Z. B., Merino, A., Tuininga, K., Wang, H., & Valamehr, B. (2022). Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. Nature Communications, 13(1), 7341. https://doi.org/10.1038/s41467-022-35123-x
Deng, X., Lee, R., Lim, S. Y., & Ding, S. (2022). Global transcriptional and epigenetic reconfiguration during chemical reprogramming of human retinal pigment epithelial cells into photoreceptor-like cells. Cells, 11(19), 3146. https://doi.org/10.3390/cells11193146
Deuse, T., Hu, X., Agbor-Enoh, S., Koch, M., Spitzer, M. H., Gravina, A., Alawi, M., Marishta, A., Peters, B., Koshal, K., & Schrepfer, S. (2019). De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans. Nature Biotechnology, 37(10), 1137--1144. https://doi.org/10.1038/s41587-019-0227-7
Eisenstein, M. (2022). Turn Biotechnologies leverages transient mRNA-based reprogramming for therapeutics. Nature Biotechnology, 40(5), 450--452. https://doi.org/10.1038/nbt-2022-05450
Fu, H., Tian, C. L., Ye, X., Sheng, X., Wang, H., Liu, Y., & Liu, L. (2018). Dynamics of telomere rejuvenation during chemical induction to pluripotent stem cells. Stem Cell Reports, 11(1), 70--87. https://doi.org/10.1016/j.stemcr.2018.05.003
Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., & Hasegawa, M. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proceedings of the Japan Academy, Series B, 85(8), 348--362. https://doi.org/10.2183/pjab.85.348
Gamm, D. M., Phillips, J. M., & Singh, R. (2013). Modeling retinal degenerative diseases with human iPS-derived cells: current status and future implications. Expert Review of Ophthalmology, 8(3), 213--216. https://doi.org/10.1586/eop.13.19
Ghosh, D., & Mehta, N. (2016). Ethical issues in biomedical use of human embryonic stem cells (hESCs). Journal of Reproductive Health and Medicine, 2(1), S37--S47. https://doi.org/10.1016/j.jrhm.2016.03.001
Gonzalo, S., Jaco, I., Fraga, M. F., Chen, T., Li, E., Esteller, M., & Blasco, M. A. (2006). DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nature Cell Biology, 8(4), 416--424. https://doi.org/10.1038/ncb1386
Gurdon, J. B. (1962). The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. Journal of Embryology and Experimental Morphology, 10(4), 622--640. https://doi.org/10.1242/dev.10.4.622
Haridhasapavalan, K. K., Borgohain, M. P., Dey, C., Saha, B., Narayan, G., Kumar, S., & Thummer, R. P. (2019). An insight into nonintegrative gene delivery approaches to generate transgene-free induced pluripotent stem cells. Gene, 686, 146--159. https://doi.org/10.1016/j.gene.2018.11.069
Harley, C. B. (1997). Telomere loss and cell senescence in human somatic cells. Journal of NIH Research, 9(3), 23--29.
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990). Telomeres shorten during ageing of human fibroblasts. Nature, 345(6274), 458--460. https://doi.org/10.1038/345458a0
He, X., Liang, J., Paul, C., Huang, W., Dutta, S., & Wang, Y. (2022). Advances in cellular reprogramming-based approaches for heart regenerative repair. Cells, 11(23), 3914. https://doi.org/10.3390/cells11233914
Hu, X., Zhang, L., Mao, S. Q., Li, Z., Chen, J., Zhang, R. R., ... & Xu, G. L. (2014). Tet and TDG mediate DNA demethylation essential for mesenchymal-to-epithelial transition in somatic cell reprogramming. Cell Stem Cell, 14(4), 512--522. https://doi.org/10.1016/j.stem.2014.01.002
Huyghe, A., Trajkova, A., & Lavial, F. (2024). Cellular plasticity in reprogramming, rejuvenation and tumorigenesis: a pioneer TF perspective. Trends in Cell Biology, 34(3), 256--264. https://doi.org/10.1016/j.tcb.2023.11.002
Ieda, M., Fu, J. D., Delgado-Olguin, P., Vedantham, V., Hayashi, Y., Bruneau, B. G., & Srivastava, D. (2010). Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell, 142(3), 375--386. https://doi.org/10.1016/j.cell.2010.07.002
Kaji, K., Norrby, K., Paca, A., Mileikovsky, M., Mohseni, P., & Woltjen, K. (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature, 458(7239), 771--775. https://doi.org/10.1038/nature07711
Kamao, H., Mandai, M., Okamoto, S., Sakai, N., Suga, A., Sugita, S., Kiryu, J., & Takahashi, M. (2014). Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports, 2(2), 205--218. https://doi.org/10.1016/j.stemcr.2013.12.007
Kanemura, H., Go, M. J., Shikamura, M., Nishishita, N., Sakai, N., Kamao, H., Mandai, M., Takahashi, M., & Kawamata, S. (2014). Tumorigenicity studies of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration. PLoS One, 9(1), e85336. https://doi.org/10.1371/journal.pone.0085336
Kim, E. J. Y., Anko, M. L., Flensberg, C., Majewski, I. J., Geng, F. S., Firas, J., Huang, D. C. S., van Delft, M. F., Heath, J. K., & Firas, J. (2018). BAK/BAX-mediated apoptosis is a Myc-induced roadblock to reprogramming. Stem Cell Reports, 10(2), 331--338. https://doi.org/10.1016/j.stemcr.2017.12.012
Kim, J., Woo, A. J., Chu, J., Snow, J. W., Fujiwara, Y., Kim, C. G., Cantor, A. B., & Orkin, S. H. (2010). A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell, 143(2), 313--324. https://doi.org/10.1016/j.cell.2010.11.016
Koche, R. P., Smith, Z. D., Adli, M., Gu, H., Ku, M., Gnirke, A., ... & Bernstein, B. E. (2011). Reprogramming factor expression initiates widespread targeted chromatin remodeling. Cell Stem Cell, 8(1), 96--105. https://doi.org/10.1016/j.stem.2010.12.001
Kustikova, O., Fehse, B., Modlich, U., Yang, M., Düllmann, J., Kamino, K., von Neuhoff, N., Schlegelberger, B., Li, Z., & Baum, C. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science, 308(5725), 1171--1174. https://doi.org/10.1126/science.1105063
Lapasset, L., Milhavet, O., Prieur, A., Besnard, E., Babled, A., Äït-Hamou, N., Leschik, J., Pellestor, F., Ramirez, J. M., De Vos, J., Lehmann, S., & Lemaitre, J. M. (2011). Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes & Development, 25(21), 2248--2253. https://doi.org/10.1101/gad.173922.111
Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Cañamero, M., Blasco, M. A., & Serrano, M. (2009). The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature, 460(7259), 1136--1139. https://doi.org/10.1038/nature08290
Li, Y. Y., & Tay, F. R. (2026). The epigenetic rejuvenation promise: Partial reprogramming as a therapeutic strategy for aging and disease. Ageing Research Reviews, 115, 103009. https://doi.org/10.1016/j.arr.2026.103009
Lu, Y., Brommer, B., Tian, X., Krishnan, A., Meer, M., Wang, C., Vera, D. L., Zeng, Q., Yu, D., Bonkowski, M. S., Yang, J. H., Zhou, S., Hoffmann, E. M., Karg, M. M., Schultz, M. B., Kane, A. E., Davidsohn, N., Korobkina, E., Chwalek, K., Rajman, L. A., Church, G. M., Hochedlinger, K., Gladyshev, V. N., Horvath, S., Levine, M. E., Gregory-Ksander, M. S., Ksander, B. R., He, Z., & Sinclair, D. A. (2020). Reprogramming to recover youthful epigenetic information and restore vision. Nature, 588(7836), 124--129. https://doi.org/10.1038/s41586-020-2975-4
Ma, C., Wang, C., Zhang, Y. F., Li, Y. Z., Fu, K., Gong, L. H., et al. (2023). Phillygenin inhibited M1 macrophage polarization and reduced hepatic stellate cell activation by inhibiting macrophage exosomal miR-125b-5p. Biomedicine & Pharmacotherapy, 159, 114264
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., Terada, M., Nomiya, Y., Muguruma, K., Hasegawa, S., Tajiri, T., Sugita, S., Kurimoto, Y., & Takahashi, M. (2017). Autologous induced stem-cell-derived retinal cells for macular degeneration. New England Journal of Medicine, 376(11), 1038--1046. https://doi.org/10.1056/NEJMoa1608368
Marión, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., & Blasco, M. A. (2009). A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature, 460(7259), 1149--1153. https://doi.org/10.1038/nature08287
Martinez, P., Gomez-Cascado, L., Garcia-Beccaria, M., & Blasco, M. A. (2010). TRF1 and telomere dynamics during the acquisition of pluripotency. Nucleic Acids Research, 38(20), 7228--7238. https://doi.org/10.1093/nar/gkq575
Matsui, S., Granitto, M., Buckley, M., Ludwig, K., Koigi, S., Shiley, J., & Iwafuchi, M. (2024). Pioneer and PRDM transcription factors coordinate bivalent epigenetic states to safeguard cell fate. Molecular Cell, 84(3), 476--489. https://doi.org/10.1016/j.molcel.2023.12.011
Mirizio, G., Sampson, S., & Iwafuchi, M. (2025). Interplay between pioneer transcription factors and epigenetic modifiers in cell reprogramming. Regenerative Therapy, 28, 246e252. https://doi.org/10.1016/j.reth.2024.12.014
Nakatsukasa, Y., Yamada, Y., & Yamada, Y. (2025). Research of in vivo reprogramming toward clinical applications in regenerative medicine: A concise review. Regenerative Therapy, 28, 12--19. https://doi.org/10.1016/j.reth.2024.11.008
Niu, W., Zang, T., Zou, Y., Whitehead, S., & Zhang, C. L. (2013). In vivo reprogramming of astrocytes into functional neurons in the adult brain. Nature Cell Biology, 15(10), 1164--1172. https://doi.org/10.1038/ncb2843
Núñez-Quintela, V., Li, H., & Collado, M. (2026). Cellular reprogramming beyond pluripotency. Trends in Molecular Medicine, 32(8), 810--819. https://doi.org/10.1016/j.molmed.2026.01.007
Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., ... & Izpisua Belmonte, J. C. (2016). In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell, 167(7), 1719--1733. https://doi.org/10.1016/j.cell.2016.11.052
Onder, T. T., Kara, N., Cherry, A., Sinha, A. U., Zhu, N., Bernt, K. M., ... & Daley, G. Q. (2012). Chromatin-modifying enzymes as modulators of reprogramming. Nature, 483(7391), 598--602. https://doi.org/10.1038/nature10953
Parrotta, E. I., Scalise, S., Scaramuzzino, L., & Cuda, G. (2019). Pluripotent stem cells for cell transplantation therapy: recent progress and future outcomes of iPSC technology. International Journal of Molecular Sciences, 20(22), 5760. https://doi.org/10.3390/ijms20225760
Puri, M. C., & Wagner, E. F. (2023). Stem cells: past, present, and future. Stem Cell Research & Therapy, 10, 68. https://doi.org/10.1186/s13287-019-1165-5
Ren, J., Zhang, X., Zhang, Z., Pan, J., Hao, Z., Li, J., & Liu, J. (2023). Apoptosis inhibition enhances induced pluripotent stem cell generation during T cell reprogramming. Biochemical and Biophysical Research Communications, 656, 30--37. https://doi.org/10.1016/j.bbrc.2023.03.024
Sabatino, D. E., Bushman, F. D., Chandler, R. J., ... & High, K. A. (2022). Evaluating the state of the science for adeno-associated virus integration: an integrated perspective. Molecular Therapy, 30(8), 2646--2663. https://doi.org/10.1016/j.ymthe.2022.06.012
Saliev, T., & Singh, P. B. (2025). Age reprogramming: Innovations and ethical considerations for prolonged longevity. Biomedical Reports, 22(1), 96. https://doi.org/10.3892/br.2024.1896
Schneider, R. P., Garrobo, I., Foronda, M., Palacios, J. A., Marión, R. M., Flores, I., Ortega, S., & Blasco, M. A. (2013). TRF1 is a stem cell marker and is essential for the generation of induced pluripotent stem cells. Nature Communications, 4, 2946. https://doi.org/10.1038/ncomms2946
Seki, T., Yuasa, S., & Fukuda, K. (2011). Derivation of induced pluripotent stem cells from human peripheral circulating T cells. Current Protocols in Stem Cell Biology, Chapter 4, Unit 4A.3. https://doi.org/10.1002/9780470151808.sc04a03s18
Sekiya, S., & Suzuki, A. (2011). Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature, 475(7356), 390--393. https://doi.org/10.1038/nature10263
Sen, C. K., Friday, A. J., & Roy, S. (2025). Cell and tissue reprogramming: Unlocking a new era in medical drug discovery. Pharmacological Reviews, 77, 100077. https://doi.org/10.1124/pharmrev.124.001077
Soma, T., Oie, Y., Takayanagi, H., Matsubara, S., Yamada, T., Nomura, M., Yoshinaga, Y., Maruyama, K., Watanabe, A., Takashima, K., & Nishida, K. (2024). Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan. The Lancet, 404(10466), 1929--1939. https://doi.org/10.1016/S0140-6736(24)01662-7
Sommer, C. A., Sommer, A. G., Longmire, T. A., Christodoulou, C., Thomas, D. D., Gostissa, M., ... & Mostoslavsky, G. (2010). Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells, 28(1), 64--74. https://doi.org/10.1002/stem.270
Son, B., Park, G. Y., Jeong, I., Kim, H., Lee, J., Joo, J., Lee, W., & Park, H. H. (2026). Next-generation immune engineering of pluripotent stem cells. Materials Today Bio, 40, 103529. https://doi.org/10.1016/j.mtbio.2026.06.038
Sugita, S., Mandai, M., Hirami, Y., Takagi, S., Maeda, T., Fujihara, M., Matsuzaki, M., Yamamoto, M., Iseki, K., Hayashi, N., Hori, T., Araki, R., Hoki, Y., Nakamura, M., Abe, M., Urano, T., Kamao, H., Okamoto, S., Jincho, Y., & Takahashi, M. (2020). HLA-matched allogeneic iPS cells-derived RPE transplantation for macular degeneration. Journal of Clinical Medicine, 9(7), 2217. https://doi.org/10.3390/jcm9072217
Suhr, S. T., Chang, E. A., Rodriguez, R. M., Wang, K., Ross, P. J., Beyhan, Z., Murthy, S., & Cibelli, J. B. (2009). Telomere dynamics in human cells reprogrammed to pluripotency. PLoS ONE, 4(12), e8124. https://doi.org/10.1371/journal.pone.0008124
Takagi, S., Mandai, M., Gocho, K., Hirami, Y., Yamamoto, M., Fujihara, M., Sugita, S., Kurimoto, Y., & Takahashi, M. (2019). Evaluation of transplanted autologous induced pluripotent stem cell-derived retinal pigment epithelium in exudative age-related macular degeneration. Ophthalmology Retina, 3(10), 850--859. https://doi.org/10.1016/j.oret.2019.04.021
Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663--676. https://doi.org/10.1016/j.cell.2006.07.024
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861--872. https://doi.org/10.1016/j.cell.2007.11.019
Takahashi, M. (2025). Quality control and release criteria for iPSC-derived cell therapy products: current standards and remaining challenges. Regenerative Medicine, 20(2), 89--101. https://doi.org/10.2217/rme-2024-0089
Thomson, J. A. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145--1147. https://doi.org/10.1126/science.282.5391.1145
Tiscornia, G., Singer, O., & Verma, I. M. (2006). Production and purification of lentiviral vectors. Nature Protocols, 1(1), 241--245. https://doi.org/10.1038/nprot.2006.38
Todd, L., Jenkins, W., Finkbeiner, C., & Fischer, A. J. (2022). Reprogramming Müller glia to regenerate ganglion-like cells in adult mouse retina with developmental transcription factors. Science Advances, 8(31), eabq7219. https://doi.org/10.1126/sciadv.abq7219
Umekage, M., Sato, Y., & Takasu, N. (2019). Overview: an iPS cell stock at CiRA. Inflammation and Regeneration, 39, 17. https://doi.org/10.1186/s41232-019-0106-0
US Department of Health and Human Services (USDHHS), National Institutes of Health, National Library of Medicine, & National Center for Biotechnology Information. (2025). Evaluation of the Safety of ER100 in People with Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions). ClinicalTrials.gov ID: NCT07290244. Accessed December 26, 2025, from https://clinicaltrials.gov/study/NCT07290244
Vierbuchen, T., Ostermeier, A., Pang, Z. P., Kokubu, Y., Südhof, T. C., & Wernig, M. (2010). Direct conversion of fibroblasts to functional neurons by defined factors. Nature, 463(7284), 1035--1041. https://doi.org/10.1038/nature08797
Wang, A., Zhang, Y., Deng, H., & Gu, M. (2026). The evolution of iPSC-based cell therapy across autologous and allogeneic pathways. Cell Reports Medicine, 7, 102992. https://doi.org/10.1016/j.xcrm.2026.102992
Wang, K., & Xiong, H. (2024). Innovative strategies for reprogramming NK cells. Molecular Therapy, 32(9), 2841. https://doi.org/10.1016/j.ymthe.2024.03.018
Wang, L., Liu, Z., Yin, C., Asfour, H., Chen, O., Li, Y., & et al. (2015). Stoichiometry of Gata4, Mef2c, and Tbx5 influences the efficiency and quality of induced cardiac myocyte reprogramming. Circulation Research, 116(2), 237--244. https://doi.org/10.1161/CIRCRESAHA.115.305141
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y. H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., & et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 7(5), 618--630. https://doi.org/10.1016/j.stem.2010.09.012
Wiegand, C., & Banerjee, I. (2019). Recent advances in the applications of iPSC technology. Current Opinion in Biotechnology, 60, 250--258. https://doi.org/10.1016/j.copbio.2019.05.006
Yehezkel, S., Rebibo-Sabbah, A., Segev, Y., ... & Selig, S. (2011). Reprogramming of telomeric regions during the generation of human induced pluripotent stem cells and subsequent differentiation into fibroblast-like derivatives. Epigenetics, 6(1), 63--75. https://doi.org/10.4161/epi.6.1.13390
Yoshida, S., Miyagawa, S., Toyofuku, T., ... & Sawa, Y. (2020). Syngeneic mesenchymal stem cells reduce immune rejection after induced pluripotent stem cell-derived allogeneic cardiomyocyte transplantation. Scientific Reports, 10(1), 4593. https://doi.org/10.1038/s41598-020-4593-y
Yoshihara, M., Hayashizaki, Y., & Murakawa, Y. (2017). Genomic instability of iPSCs: Challenges towards their clinical applications. Stem Cell Reviews and Reports, 13(1), 7--16. https://doi.org/10.1007/s12015-016-9701-3
Zhang, H., Guo, Y., Yang, Y., & Ding, S. (2023). MAP4Ks inhibition promotes retinal neuron regeneration from Müller glia in adult mice. NPJ Regenerative Medicine, 8, 36. https://doi.org/10.1038/s41536-023-00295-8
Zhao, T., Zhang, Z. N., Rong, Z., & Xu, Y. (2011). Immunogenicity of induced pluripotent stem cells. Nature, 474(7350), 212--215. https://doi.org/10.1038/nature10135